U.S. MarketsAugust 24 at 06:32 AM

Gilead (GILD) announced that the European Commission (EC) has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda for treatment of triple-negative breast cancer

StockNow breaking-news AI analysis

Gilead secured EC authorization for Trodelvy plus Keytruda in triple-negative breast cancer as Trodelvy revenue climbed 26% to $457M, bolstering oncology franchise expansion.

2 stocks

GILDGilead Sciences Inc$146.58Current price

MRKMerck & Co., Inc.$151.99Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

Politics

USTR Greer, when asked about what US Treasury Secretary Bessent may say later, says US President Trump is comfortable with using all levers at his disposal, remarks via CNBC

Geopolitics

US Treasury is expected to announce it will broaden the scope of secondary sanctions on nations/entities conducting business with Iran, according to sources. Any activity within some Iranian sectors will reportedly be subject to secondary sanctions.